Aspen (APN), South Africa’s largest listed pharmaceutical company, today announced that it has reached an agreement with Roche to produce a generic version of oseltamivir for Africa. This complements Roche’s continued efforts to increase and speed up availability of the medicine for world wide influenza pandemic planning. The agreement focuses on providing oseltamivir for pandemic… Continue reading Aspen to manufacture influenza medicine oseltamivir
Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.
